Analysis of the chemotherapy-free interval following image-guided ablation in sarcoma patients Journal Article
| Authors: | Sutton, C.; Zhang, Y.; Kim, D.; Yarmohammadi, H.; Ziv, E.; Boas, F. E.; Sofocleous, C. T.; Tap, W. D.; D'Angelo, S. P.; Erinjeri, J. P. |
| Article Title: | Analysis of the chemotherapy-free interval following image-guided ablation in sarcoma patients |
| Abstract: | One way to enhance quality of life for patients with metastatic sarcoma is to maximize time off chemotherapy - a chemotherapy-free interval. While image-guided ablation of sarcoma metastases may reduce the need for chemotherapy, it remains unknown how long ablation could extend the chemotherapy-free interval. The purpose of our study was to determine the chemotherapy-free interval in comparison to overall survival and progression-free survival in sarcoma patients who undergo ablation procedures. An IRB-approved, single institution, HIPAA compliant database was queried for sarcoma patients who underwent image-guided ablation procedures between 2007 and 2018. Patient demographics, histologic subtype, and other clinical characteristics were recorded. Kaplan-Meier analysis was performed to compute median overall survival, median progression-free survival (local and distant), and the median chemotherapy-free interval (systemic and cytotoxic) after ablation. Univariate and multivariate analyses were performed using the log-rank test and Cox proportional-hazards model, respectively. A total of 100 sarcoma patients were included in the analysis. The most common histologic subtype was leiomyosarcoma (38%). Median overall survival after ablation of sarcoma metastases was 52.4 months (95% CI: 46.9-64.0 months). The median systemic chemotherapy-free interval following ablation of sarcoma metastases was 14.7 months (95% CI: 8.6-34.3 months). The median cytotoxic chemotherapy-free interval following ablation of sarcoma metastases was 81.3 months (95% CI: 34.3-median not reached). In conclusion, ablation of sarcoma metastases can provide an extended systemic chemotherapy-free interval of greater than 1 year. Ablation of sarcoma metastases may improve patient quality of life by extending the chemotherapy-free interval. © 2020 Charles Sutton et al. |
| Keywords: | adult; cancer chemotherapy; human tissue; middle aged; major clinical study; overall survival; cancer patient; metastasis; progression free survival; quality of life; sarcoma; leiomyosarcoma; ablation therapy; human; male; female; article |
| Journal Title: | Sarcoma |
| Volume: | 2020 |
| ISSN: | 1357-714X |
| Publisher: | Hindawi Publishing Corporation |
| Date Published: | 2020-02-15 |
| Start Page: | 3852420 |
| Language: | English |
| DOI: | 10.1155/2020/3852420 |
| PROVIDER: | scopus |
| PMCID: | PMC7044489 |
| PUBMED: | 32148436 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
252D'Angelo -
200Erinjeri -
244Sofocleous -
372Tap -
8Zhang -
131Yarmohammadi -
77Boas -
111Ziv -
3
Sutton -
9Kim
Related MSK Work